Skip to main content
SpringerLink
Log in

Economic Burden of Heart Failure in the Elderly

  • Leading Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Heart failure (HF) ranks among the most costly chronic diseases in developed countries. At present these countries devote 1–2% of all healthcare expenditures towards HF. In the US, these costs are estimated at $US30.2 billion for 2007. The burden of HF is greatest among the elderly, with 80% of HF hospitalizations and 90% of HF-related deaths in this cohort. As a result, approximately three-quarters of the resources for HF care are consumed by elderly patients. As demographic shifts increase the number of elderly individuals in both developed and developing nations, the resources devoted to HF care will likely further increase.

Hospitalization accounts for roughly two-thirds of HF costs, but procedures, outpatient visits and medications also consume significant financial resources. HF also adversely impacts patient quality of life, and these relevant effects may not be captured in pure cost analyses. The cost effectiveness of several pharmacological interventions has been explored. In general, neurohormonal antagonists used for outpatient treatment of chronic HF are relatively cost effective, in part by reducing hospitalizations.

Because HF poses such an enormous financial burden, efficient resource allocation for its management is a major societal and governmental challenge. In order to make informed decisions and allocate resources for HF care rationally, detailed data regarding costs and resource use will be essential. Further studies are needed to examine the impact of pharmacological and non-pharmacological interventions on costs and resource use in elderly individuals with HF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur Heart J 1999; 20: 447–455

    Article  PubMed  CAS  Google Scholar 

  2. Redfield MM, Jacobsen SJ, Burnett Jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202

    Article  PubMed  Google Scholar 

  3. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics: 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69–e171

    Article  PubMed  Google Scholar 

  4. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. Am Heart J 1998; 135: S285–S292

    Article  PubMed  CAS  Google Scholar 

  5. Haldeman GA, Croft JB, Giles WH, et al. Hospitalization of patients with heart failure: national hospital discharge survey, 1985 to 1995. Am Heart J 1999; 137: 352–360

    Article  PubMed  CAS  Google Scholar 

  6. Croft JB, Giles WH, Pollard RA, et al. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc 1997; 45: 270–275

    PubMed  CAS  Google Scholar 

  7. Ryden-Bergsten T, Adersson F. Health care costs of heart failure in Sweden. J Intern Med 1999; 246: 275–284

    Article  PubMed  CAS  Google Scholar 

  8. Lee WC, Chavez YE, Baker T, et al. Economic burden of heart failure: a summary of recent literature. Heart Lung 2004; 33: 362–371

    Article  PubMed  Google Scholar 

  9. Berry C, Murdoch DR, McMurray JJV. Economics of chronic heart failure. Euro J Heart Fail 2001; 3: 283–291

    Article  CAS  Google Scholar 

  10. Kitzman D, Gardin J, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. Am J Cardiol 2001; 87: 413–419

    Article  PubMed  CAS  Google Scholar 

  11. Hogg K, Swedberg K, McMurray J. Heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 2004; 43: 317–327

    Article  PubMed  Google Scholar 

  12. de Giuli F, Khaw KT, Cowie MR, et al. Incidence and outcome of persons with a clinical diagnosis of heart failure in a general practice population of 696 884 in the United Kingdom. Eur J Heart Fail 2005; 7: 295–302

    Article  PubMed  Google Scholar 

  13. Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure: a population-based study. Eur Heart J 1999; 20: 421–428

    Article  PubMed  CAS  Google Scholar 

  14. McMurray J, McDonagh T, Morrison CE, et al. Trends in hospitalization for heart failure in Scotland 1980–1990. Eur Heart J 1993; 14: 1158–1162

    Article  PubMed  CAS  Google Scholar 

  15. Gaasch WH. Diagnosis and treatment of heart failure based on left ventricular systolic or diastolic dysfunction. JAMA 1994; 271: 1276–1280

    Article  PubMed  CAS  Google Scholar 

  16. Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259

    Article  PubMed  CAS  Google Scholar 

  17. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260–269

    Article  PubMed  CAS  Google Scholar 

  18. Lenzen MJ, Scholte op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur Heart J 2004; 25: 1214–1220

    Article  PubMed  CAS  Google Scholar 

  19. Stewart S, Jenkins A, Buchan S, et al. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4: 361–371

    Article  PubMed  Google Scholar 

  20. Rodriguez-Artalejo F, Guallar-Castillon P, Banegas Jr B, et al. Trends in hospitalization and mortality for heart failure in Spain, 1980–1993. Eur Heart J 1997; 18: 1771–1779

    Article  PubMed  CAS  Google Scholar 

  21. Launois R, Launois B, Reboul-Marty J, et al. Le cout de la severite de la maladie: le cas de rinsuffisance-cardiaque. J Econ Med 1990; 8: 395–312

    Google Scholar 

  22. Agvall B, Borgquist L, Foldevi M, et al. Cost of heart failure in Swedish primary healthcare. Scand J Prim Health Care 2005; 23: 227–232

    Article  PubMed  Google Scholar 

  23. Meerding WJ, Bonneux L, Polder J J, et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. Br Med J 1998; 317: 111–116

    Article  CAS  Google Scholar 

  24. McMurray J, Hart W, Rhodes G. An evaluation of the cost of heart failure to the national health service in the UK. Br J Med Econ 1993; 6: 91–98

    Google Scholar 

  25. Centers for Medicare and Medicaid Services and Office of the Actuary. National health expenditure projections 2006–2016. Baltimore (MD): Centers for Medicare and Medicaid Services, 2006 [online]. Available from URL: http://www.cms.hhs.gov/NationalHealthExpendData/downloads/proj2006.pdf [Accessed 2007 Dec 17]

    Google Scholar 

  26. Ng TP, Niti M. Trends and ethnic differences in hospital admissions and mortality for congestive heart failure in the elderly in Singapore, 1991 to 1998. Heart 2003; 89: 865–870

    Article  PubMed  CAS  Google Scholar 

  27. Feldman DE, Thivierge C, Guerard L, et al. Changing trends in mortality and admissions to hospital for elderly patients with congestive heart failure in Montreal. CMAJ 2001; 165: 1033–1036

    PubMed  CAS  Google Scholar 

  28. Foot DK, Lewis RP, Pearson TA, et al. Demographics and cardiology, 1950–2050. J Am Coll Cardiol 2000; 35: 1067–1081

    Article  PubMed  CAS  Google Scholar 

  29. Masoudi FA, Havranek EP, Krumholz HM. The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. Heart Fail Rev 2002; 7: 9–16

    Article  PubMed  Google Scholar 

  30. Stewart S, Maclntyre K, Capewell S, et al. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003; 89: 49–53

    Article  PubMed  CAS  Google Scholar 

  31. Polanczyk CA, Rohde LE, Dec GW, et al. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med 2000; 160: 325–332

    Article  PubMed  CAS  Google Scholar 

  32. Malek M. Health economics of heart failure. Heart 1999; 82: IV11–IV13

    PubMed  Google Scholar 

  33. Stroupe KT, Forthofer MM, Brater DC, et al. Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmacoeconomics 2000; 17: 429–440

    Article  PubMed  CAS  Google Scholar 

  34. Cowie MR, Fox KF, Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. Eur Heart J 2002; 23: 877–885

    Article  PubMed  CAS  Google Scholar 

  35. Wexler DJ, Chen J, Smith GL, et al. Predictors of costs of caring for elderly patients discharged with heart failure. Am Heart J 2001; 142: 350–357

    Article  PubMed  CAS  Google Scholar 

  36. Cleland JG, Swedberg K, Follath F, et al. TheEuroHeart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442–463

    Article  PubMed  CAS  Google Scholar 

  37. Fonarow GC, Heywood JT, Heidenreich PA, et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2007; 153: 1021–1028

    Article  PubMed  Google Scholar 

  38. Mark DB. Economics of treating heart failure. Am J Cardiol 1997; 80: 33H–38H

    Article  PubMed  CAS  Google Scholar 

  39. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001–02. Vital Health Stat 13 2006 Feb; (159): 1–66

    PubMed  Google Scholar 

  40. Liao L, Anstrom KJ, Gottdiener JS, et al. Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. Am Heart J 2007; 153: 245–252

    Article  PubMed  Google Scholar 

  41. Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998–2001. Arch Intern Med 2005; 165: 2069–2076

    Article  PubMed  Google Scholar 

  42. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme: a survey on the quality of care among patients with heart failure in Europe. Part II: treatment. Eur Heart J 2003; 24: 464–474

    Article  PubMed  CAS  Google Scholar 

  43. Cleland JG, Cohen-Solal A, Aguilar JC, et al. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 2002; 360: 1631–1639

    Article  PubMed  CAS  Google Scholar 

  44. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–1195

    Article  PubMed  CAS  Google Scholar 

  45. Davey PG, Clarkson PB, McMahon A, et al. Costs associated with symptomatic systolic heart failure. Pharmacoeconomics 1999; 16: 399–407

    Article  PubMed  CAS  Google Scholar 

  46. Philbin EF, Rocco Jr TA, Lindenmuth NW, et al. Systolic versus diastolic heart failure in community practice: clinical features, outcomes, and the use of angiotensin-converting enzyme inhibitors. Am J Med 2000; 109: 605–613

    Article  PubMed  CAS  Google Scholar 

  47. Liao L, Jollis JG, Anstrom KJ, et al. Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 2006; 166: 112–118

    Article  PubMed  Google Scholar 

  48. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: el54–el235

    Article  Google Scholar 

  49. Reed SD, Friedman JY, Velazquez EJ, et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004; 148: 122–128

    Article  PubMed  Google Scholar 

  50. Auerbach AD, Hamel MB, Davis RB, et al. Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician. SUPPORT Investigators: Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 2000; 132: 191–200

    PubMed  CAS  Google Scholar 

  51. Weintraub WS, Kawabata H, Tran M, et al. Influence of comorbidity on cost of care for heart failure. Am J Cardiol 2003; 91: 1011–1015, A8

    Article  PubMed  Google Scholar 

  52. Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics 1999; 16: 247–271

    Article  PubMed  CAS  Google Scholar 

  53. Ekman I, Fagerberg B, Lundman B. Health-related quality of life and sense of coherence among elderly patients with severe chronic heart failure in comparison with healthy controls. Heart Lung 2002; 31: 94–101

    Article  PubMed  Google Scholar 

  54. Heo S, Moser DK, Lennie TA, et al. A comparison of health-related quality of life between older adults with heart failure and healthy older adults. Heart Lung 2007; 36: 16–24

    Article  PubMed  Google Scholar 

  55. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail 2005; 7: 243–251

    Article  PubMed  Google Scholar 

  56. Rao A, Asadi-Lari M, Walsh J, et al. Quality of life in patients with signs and symptoms of heart failure: does systolic function matter? J Card Fail 2006; 12: 677–683

    Article  PubMed  Google Scholar 

  57. Weintraub WS, Cole J, Tooley JF. Cost and cost-effectiveness studies in heart failure research. Am Heart J 2002; 143: 565–576

    Article  PubMed  Google Scholar 

  58. Weintraub WS, Zhang Z, Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005; 111: 1106–1113

    Article  PubMed  Google Scholar 

  59. Skrepnek GH, Abarca J, Malone DC, et al. Incremental effects of concurrent pharmacotherapeutic regimens for heart failure on hospitalizations and costs. Ann Pharmacother 2005; 39: 1785–1791

    Article  PubMed  Google Scholar 

  60. Del Sindaco D, Pulignano G, Minardi G, et al. Two-year outcome of a prospective, controlled study of a disease management programme for elderly patients with heart failure. J Cardiovasc Med (Hagerstown) 2007; 8: 324–329

    Article  Google Scholar 

  61. Sanders GD, Hlatky MA, Every NR, et al. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. Ann Intern Med 2001 Nov 20; 135 (10): 870–883

    PubMed  CAS  Google Scholar 

  62. Yao G, Freemantle N, Calvert MJ, et al. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J 2007; 28: 42–51

    Article  PubMed  CAS  Google Scholar 

  63. Clegg AJ, Scott DA, Loveman E, et al. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation. Int J Technol Assess Health Care 2007; 23: 261–268

    Article  PubMed  Google Scholar 

  64. Ward RE, Gheorghiade M, Young JB, et al. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J Am Coll Cardiol 1995; 26: 93–101

    Article  PubMed  CAS  Google Scholar 

  65. Eisenstein EL, Yusuf S, Bindal V, et al. What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. J Card Fail 2006; 12: 336–342

    Article  PubMed  Google Scholar 

  66. Schadlich PK, Paschen B, Brecht JG. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany. Pharmacoeconomics 1998; 13: 147–155

    Article  PubMed  CAS  Google Scholar 

  67. Levy P, Lechat P, Leizorovicz A, et al. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998; 12: 301–305

    Article  PubMed  CAS  Google Scholar 

  68. Di Stasi F, Sealone L, De Portu S, et al. Cost-effectiveness analysis of bisoprolol treatment for heart failure. Ital Heart J 2005; 6: 950–955

    PubMed  Google Scholar 

  69. Ekman M, Zethraeus N, Jonsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics 2001; 19: 901–916

    Article  PubMed  CAS  Google Scholar 

  70. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur Heart J 2001; 22 (12): 1021-31

  71. Caro JJ, Migliaccio-Walle K, O’Brien JA, et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. J Card Fail 2005; 11: 647–656

    Article  PubMed  CAS  Google Scholar 

  72. Fowler MB, Vera-Llonch M, Oster G, et al. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. US Carvedilol Heart Failure Study Group. J Am Coll Cardiol 2001; 37: 1692–1699

    Article  PubMed  CAS  Google Scholar 

  73. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651–1658

    Article  PubMed  CAS  Google Scholar 

  74. Stewart S, McMurray JJ, Hebborn A, et al. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. Int J Cardiol 2005; 100: 143–149

    Article  PubMed  Google Scholar 

  75. Levy AR, Briggs AH, Demers C, et al. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 2001; 142: 537–543

    Article  PubMed  CAS  Google Scholar 

  76. Szucs TD, Holm MV, Schwenkglenks M, et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction: an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther 2006; 20: 193–204

    Article  PubMed  Google Scholar 

  77. Spannheimer A, Goertz A, Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract 1998; 52: 467–471

    PubMed  CAS  Google Scholar 

  78. Noe LL, Vreeland MG, Pezzella SM, et al. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clin Ther 1999; 21: 854–866

    Article  PubMed  CAS  Google Scholar 

  79. Heaton AH, Bryant J, Berman BN, et al. Pharmacoeconomic comparison of loop diuretics in the treatment of congestive heart failure. Med Interface 1996; 9: 101–107

    PubMed  CAS  Google Scholar 

  80. Glick HA, Orzol SM, Tooley JF, et al. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther 2002; 16: 53–59

    Article  PubMed  CAS  Google Scholar 

  81. Tilson L, McGowan B, Ryan M, et al. Cost-effectiveness of spironolactone in patients with severe heart failure. Ir J Med Sci 2003; 172: 70–72

    Article  PubMed  CAS  Google Scholar 

  82. Abarca J, Malone DC, Armstrong EP, et al. Angiotensin-con-verting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organization: effect on costs and probability of hospitalization Pharmacotherapy 2004; 24: 351–357

    Article  PubMed  CAS  Google Scholar 

  83. Schwartz JS, Wang YR, Cleland JG, et al. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial. Am J Manag Care 2003; 9: 417–424

    PubMed  Google Scholar 

  84. Sculpher MJ, Poole L, Cleland J, et al. Low doses vs high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. Eur J Heart Fail 2000; 2: 447–454

    Article  PubMed  CAS  Google Scholar 

  85. Paul SD, Kuntz KM, Eagle KA, et al. Costs and effectiveness of angiotensin converting enzyme inhibition in patients with congestive heart failure. Arch Intern Med 1994; 154: 1143–1149

    Article  PubMed  CAS  Google Scholar 

  86. Glick H, Cook J, Kinosian B, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) treatment trial. J Card Fail 1995; 1: 371–380

    Article  PubMed  CAS  Google Scholar 

  87. Angus DC, Linde-Zwirble WT, Tam SW, et al. Cost-effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine therapy for blacks with heart failure. Circulation 2005; 112: 3745–3753

    Article  PubMed  Google Scholar 

  88. Reed SD, Radeva JI, Weinfurt KP, et al. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). Am Heart J 2005; 150: 323–329

    Article  PubMed  Google Scholar 

  89. McMurray JJ, Andersson FL, Stewart S, et al. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006; 27: 1447–1458

    Article  PubMed  Google Scholar 

  90. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450–1456

    Article  PubMed  CAS  Google Scholar 

  91. Hummel S, Piercy J, Wright R, et al. An economic analysis of the Survival and Ventricular Enlargement (SAVE) study: application to the United Kingdom. Pharmacoeconomics 1997; 12: 182–192

    Article  PubMed  CAS  Google Scholar 

  92. Boyko Jr WL, Glick HA, Schulman KA. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies: ACE inhibitors in the management of congestive heart failure. Comparative economic data. Am Heart J 1999; 137: S115–S119

    Article  PubMed  Google Scholar 

  93. McMurray J J, McGuire A, Davie AP, et al. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J 1997; 18: 1411–1415

    Article  PubMed  CAS  Google Scholar 

  94. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–771

    Article  PubMed  CAS  Google Scholar 

  95. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1906

    Article  PubMed  CAS  Google Scholar 

  96. Gilbert EM. Cost-effectiveness of beta-blocker treatment in heart failure. Rev Cardiovasc Med 2002; 3 Suppl. 3: S42–S47

    PubMed  Google Scholar 

  97. Cowper PA, DeLong ER, Whellan DJ, et al. Economic effects of beta-blocker therapy in patients with heart failure. Am J Med 2004; 116: 104–111

    Article  PubMed  CAS  Google Scholar 

  98. Delea TE, Stanford R, Hagiwara M, et al. Death and hospitalization in heart failure patients receiving carvedilol vs metoprolol tartrate. Int J Cardiol 2005; 99: 117–124

    Article  PubMed  Google Scholar 

  99. Croom KF, Plosker GL. Eplerenone: a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure. Pharmacoeconomics 2005; 23: 1057–1072

    Article  PubMed  CAS  Google Scholar 

  100. Young M, Plosker GL. Torasemide: a pharmacoeconomic review of its use in chronic heart failure. Pharmacoeconomics 2001; 19: 679–703

    Article  PubMed  CAS  Google Scholar 

  101. Philbin EF, Rocco TA. Use of angiotensin-converting enzyme inhibitors in heart failure with preserved left ventricular systolic function. Am Heart J 2001; 134: 188–195

    Article  Google Scholar 

  102. Taylor DH, Whellan DJ, Sloan FA. Effects of admission to a teaching hospital on the cost and quality of care for medicare beneficiaries. N Engl J Med 1999; 340: 293–299

    Article  PubMed  Google Scholar 

  103. Jollis JG, Ancukiewicz M, DeLong ER, et al. Discordance of databases designed for claims payment versus clinical information systems: implications for outcomes research. Ann Intern Med 1993; 119: 844–850

    PubMed  CAS  Google Scholar 

  104. Psaty BM, Boineau R, Kuller LH, et al. The potential costs of upcoding for heart failure in the United States. Am J Cardiol 1999; 84: 108–109

    Article  PubMed  CAS  Google Scholar 

  105. Khand AU, Shaw M, Gemmel I, et al. Do discharge codes underestimate hospitalisation due to heart failure? Validation study of hospital discharge coding for heart failure. Eur J Heart Fail 2005; 7: 792–797

    Article  PubMed  Google Scholar 

  106. Philbin EF, McCullough PA, Dec GW, et al. Length of stay and procedure utilization are the major determinants of hospital charges for heart failure. Clin Cardiol 2001; 24: 56–62

    Article  PubMed  CAS  Google Scholar 

  107. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995; 333: 1190–1195

    Article  PubMed  CAS  Google Scholar 

  108. Linne AB, Liedholm H, Jendteg S, et al. Health care costs of heart failure: results from a randomised study of patient education. Euro J Heart Fail 2000; 2: 291–297

    Article  CAS  Google Scholar 

  109. Starling RC. The heart failure pandemic: changing patterns, costs, and treatment strategies. Cleve Clin J Med 1998; 65: 351–358

    PubMed  CAS  Google Scholar 

  110. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–115

    Article  PubMed  CAS  Google Scholar 

  111. Bennett SJ, Saywell RM, Zollinger TW, et al. Cost of hospitalizations for heart failure: sodium retention versus other decompensating factors. Heart Lung 1999; 28: 102–109

    Article  PubMed  CAS  Google Scholar 

  112. Ni H, Nauman DJ, Hershberger RE. Analysis of trends in hospitalizations for heart failure. J Cardiac Fail 1999; 5: 79–84

    Article  CAS  Google Scholar 

  113. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766

    Article  PubMed  CAS  Google Scholar 

  114. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675

    Article  PubMed  CAS  Google Scholar 

  115. Cleland JG, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338–2345

    Article  PubMed  CAS  Google Scholar 

  116. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–225

    Article  PubMed  CAS  Google Scholar 

  117. Carson P, Massie BM, McKelvie R, et al. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design. J Card Fail 2005; 11: 576–585

    Article  PubMed  CAS  Google Scholar 

  118. Allen LA, O’Connor CM. Management of acute decompensated heart failure. CMAJ 2007; 176: 797–805

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no potential conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. The Duke Clinical Research Institute, Durham, North Carolina, USA

    Lawrence Liao & Larry A. Allen

  2. The Jefferson Heart Institute, Philadelphia, Pennsylvania, USA

    David J. Whellan

Authors
  1. Lawrence Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry A. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David J. Whellan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence Liao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liao, L., Allen, L.A. & Whellan, D.J. Economic Burden of Heart Failure in the Elderly. Pharmacoeconomics 26, 447–462 (2008). https://doi.org/10.2165/00019053-200826060-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200826060-00001

Keywords

Search

Navigation